These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24016786)

  • 1. New antiplatelet agents for cardiovascular disease.
    Chua D; Nishi C
    CMAJ; 2013 Nov; 185(16):1405-11. PubMed ID: 24016786
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
    Tapp L; Shantsila E; Lip GY
    Circulation; 2010 Mar; 121(10):1169-71. PubMed ID: 20194888
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents.
    Tagarakis GI
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):208-11. PubMed ID: 20874669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
    Wong YW; Prakash R; Chew DP
    Curr Opin Cardiol; 2010 Jul; 25(4):305-11. PubMed ID: 20421791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
    Postuła M; Akram S; Akram F
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):55-60. PubMed ID: 19149707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Kern MJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
    [No Abstract]   [Full Text] [Related]  

  • 9. [Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
    Stiefelhagen P
    MMW Fortschr Med; 2013 Feb; 155(3):18. PubMed ID: 23573760
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
    Floyd CN; Passacquale G; Ferro A
    Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
    Schömig A
    N Engl J Med; 2009 Sep; 361(11):1108-11. PubMed ID: 19717845
    [No Abstract]   [Full Text] [Related]  

  • 12. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
    Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
    Sousa-Uva M; Storey R; Huber K; Falk V; Leite-Moreira AF; Amour J; Al-Attar N; Ascione R; Taggart D; Collet JP;
    Eur Heart J; 2014 Jun; 35(23):1510-4. PubMed ID: 24748565
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
    Cairns JA; Eikelboom J
    J Am Coll Cardiol; 2008 Dec; 52(24):1978-80. PubMed ID: 19055988
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
    Steiner S; Moertl D
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):975-84. PubMed ID: 23984925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
    Alber HF; Huber K; Pachinger O; Frick M
    Wien Klin Wochenschr; 2011 Aug; 123(15-16):468-76. PubMed ID: 21800048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Norgard NB; Dinicolantonio JJ
    Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.